Spin-offs

Gate2Brain was founded in 2020 as a result of research devoted to peptides with the capacity to cross the Blood-Brain Barrier (BBB) and simultaneously carry therapeutic molecules. The flagship product, G2B-001, is a promising therapy for a paediatric brain tumour, for which there is no cure.

Ona Therapeutics was launched in 2019 and is specialised in the discovery and development of therapeutic biologics targeting tumour metastasis-initiating cells and lipid metabolism. This therapeutic approach has the potential to prevent the formation of metastases and eliminate existing ones in multiple types of cancer. In 2020, Ona Therapeutics closed a large series A 30M investment round with an international expert syndicate of VCs.

<p>Logo Nostrum Biodiscovery</p>

Nostrum Biodiscovery is a biotech company that was founded in 2015. It is focused on the computational biology sector, particularly on the field of structure-based drug design dedicated to early drug discovery and development based on rational design techniques.

Inbiomotion is a Barcelona-based company dedicated to personalised medicine that was set up in 2011. It pursues the development of biomarkers that predict bone metastasis, thereby improving the quality of life of cancer patients.

Iproteos (now Accure Therapeutics) was a biotech company devoted to the research and development of third-generation drugs based on peptidomimetics for human diseases. The company’s strategy was based on peptidomimetics, molecules able to modulate the activity of undruggable targets such as Protein-Protein Interactions (PPIs). It was created in 2011 and in 2020 was taken over by Accure Therapeutics to create a strong company working in CNS therapies.

Omnia Molecular was launched in 2006 and suspended activity in 2016. It was devoted to the design and development of anti-infectives targeting difficult-to-treat infections. Lead compounds were synthesised and optimised using a proprietary technology platform and proved effective in several biological assays.